HCV Replication Inhibition via NS5A Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis C virus (HCV) infection, such as peginterferon-alpha and ribavirin, suffer from substantial limitations in efficacy and tolerability due to side effects and inadequate viral elimination, and existing drugs have not effectively targeted the virus's non-structural proteins for replication inhibition.
Innovation Solution
Development of compounds with specific Formulae I, I(a), I(b), I(c), I(d), I(e), or I(h) structures, or their tautomers and pharmaceutically acceptable salts, which can inhibit HCV replication by targeting non-structural proteins, particularly NS5A, and be used alone or in combination with other antiviral agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peginterferon-alpha and ribavirin are used for HCV treatment, then viral elimination is achieved to some extent, but side effects increase and tolerability decreases
Solution Approach 1:
The patent extracts and targets specific viral non-structural proteins (NS3, NS4A, NS4B, NS5A, NS5B) as separate inhibition targets, rather than using broad-spectrum antivirals like interferon. This selective extraction of viral functions for targeted inhibition reduces off-target effects on host cells, thereby reducing side effects while maintaining antiviral efficacy.
Solution Approach 2:
The patent introduces small molecule inhibitors as intermediary substances that specifically bind to viral non-structural proteins, acting as mediators between the therapeutic goal (viral inhibition) and the target (viral proteins). These intermediaries provide more precise and controllable viral inhibition compared to cytokine-based therapies like interferon, reducing harmful side effects.
2Ease of operation
If peginterferon-alpha is used with extended half-life, then compliance is enhanced, but viral elimination remains inadequate
Solution Approach 1:
The patent changes the molecular parameters of the therapeutic agents by developing small molecule inhibitors with optimized binding affinity and selectivity for viral non-structural proteins. These compounds have improved pharmacological parameters including potency, selectivity, and pharmacokinetic properties, achieving better viral elimination efficacy while maintaining compliance through various dosing regimens.
3Reliability
If existing antiviral drugs are used, then some viral inhibition is achieved, but they do not effectively target non-structural proteins
Solution Approach 1:
The patent segments the viral polyprotein into individual non-structural protein targets (NS3, NS4A, NS4B, NS5A, NS5B) and develops specific inhibitors for each segment. This segmentation allows for targeted inhibition of specific viral functions, providing versatile and adaptable therapy that can address different aspects of viral replication independently.
Solution Approach 2:
The patent creates a multi-functional therapeutic approach by developing inhibitors that can target multiple non-structural proteins or by using combination therapies that address different viral functions. This universal approach enhances the ability to effectively inhibit viral replication through multiple mechanisms simultaneously.
Data Source
AI summary
Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.